Kestra Private Wealth Services LLC Makes New $833,000 Investment in Genmab A/S Sponsored ADR $GMAB

Kestra Private Wealth Services LLC acquired a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 27,061 shares of the company’s stock, valued at approximately $833,000.

Several other institutional investors and hedge funds have also recently modified their holdings of GMAB. NewEdge Advisors LLC lifted its holdings in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares in the last quarter. Brown Brothers Harriman & Co. grew its stake in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares in the last quarter. Founders Capital Management increased its holdings in Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares during the last quarter. Community Bank N.A. purchased a new stake in Genmab A/S in the 3rd quarter worth $47,000. Finally, Cromwell Holdings LLC lifted its stake in Genmab A/S by 136.3% in the 3rd quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after purchasing an additional 883 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

GMAB stock opened at $26.45 on Monday. Genmab A/S Sponsored ADR has a 52 week low of $18.89 and a 52 week high of $35.43. The firm has a market capitalization of $16.49 billion, a P/E ratio of 17.06, a price-to-earnings-growth ratio of 1.18 and a beta of 0.86. The company has a fifty day simple moving average of $27.43 and a two-hundred day simple moving average of $30.03. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 18th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. Analysts anticipate that Genmab A/S Sponsored ADR will post 1.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wolfe Research started coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective for the company. Truist Financial upgraded Genmab A/S to a “strong-buy” rating in a research report on Monday, April 27th. Jefferies Financial Group began coverage on Genmab A/S in a research note on Tuesday, February 17th. They set a “buy” rating and a $41.50 price target for the company. Morgan Stanley started coverage on Genmab A/S in a report on Monday, February 16th. They set an “equal weight” rating and a $34.00 price target for the company. Finally, Wells Fargo & Company began coverage on Genmab A/S in a research note on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $39.07.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.